Novartis AG (NVS) News
Track canonical SquawkNews coverage tagged to NVS, Novartis AG. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 38 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Trending stocks this week as markets end lower amid inflation, yield jitters
Wall Street ended the week lower, with investors digesting a sharp rise in Treasury yields and the latest inflation data.The benchmark 10-year yield climbed nearly 20 bps to 4.97%, while CPI rose 0.4% M/M in August, in l
MACRO | Sep 13, 2026, 02:01 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
Notable analyst calls this week: Lockheed Martin, Meta and Intel among top picks
The S&P 500 (SP500) closed in the green on Friday, after the week saw the latest consumer inflation report coming in largely in line with expectations, as well as earnings reports from companies including Oracle and Adob
EARNINGS | Sep 12, 2026, 02:11 PM UTC
L
Olema drops after hours on AstraZeneca Etcamah data
Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser
NEWS | Sep 11, 2026, 10:33 PM UTC
H
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback
The Nasdaq Composite Index NYSE:COMP climbed on Friday alongside major Wall Street indexes after the latest consumer inflation report came in largely in line with expectations. It closed +0.96% higher after jumping by ov
NEWS | Sep 11, 2026, 08:31 PM UTC
L
Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
Novartis NYSE:NVS, the global innovative-medicines company, confronted sharper questions over its dealmaking strategy Friday after clinical setbacks weakened confidence in recent acquisitions. Its U.S.-listed shares trad
EQUITY | Sep 11, 2026, 08:01 PM UTC
L
Novartis shares rebound 0.8% to $138.545 after board challenge
Novartis shares (NYSE:NVS) rose 0.8% to $138.545 on Thursday. The move came after Artisan Partners investor David Samra called for tougher board oversight, including strengthening the acquisition review process and a ded
EQUITY | Sep 10, 2026, 06:31 PM UTC
L
Novartis facing board change threat from shareholder following trial failures
A large Novartis NYSE:NVS shareholder is calling for changes on the Swiss pharma giant's board in the aftermath of two phase 3 drug trial setbacks in the last few weeks.Artisan Partners Managing Director David Samra told
MNA | Sep 10, 2026, 02:33 PM UTC
L
Novartis shares slip again after Deutsche Bank downgrade
Novartis shares fell for a third straight session on Wednesday after Deutsche Bank downgraded the company, citing failures in a pair of late-stage trials that had driven the stock lower in the prior session.
EQUITY | Sep 09, 2026, 05:42 PM UTC
L
RBC starts EU pharma coverage with Outperform ratings for AstraZeneca, Roche
RBC Capital Markets launched EU pharma coverage: Outperform for AstraZeneca and Roche, and Sector Perform for Sanofi, Novartis and GSK.
EQUITY | Sep 09, 2026, 02:43 PM UTC
L
Dyne Therapeutics slides after J.P. Morgan downgrade tied to Novartis setback
Dyne Therapeutics (DYN) traded lower in premarket after J.P. Morgan downgraded the neuromuscular disease company, citing a study setback affecting a Novartis (NVS) medicine and share pressure in the prior session.
EQUITY | Sep 09, 2026, 01:21 PM UTC
M
Novartis shares drop after del-desiran misses trial endpoint
Novartis stock fell 10.1% to $138.51 after del-desiran missed the primary endpoint in a myotonic-dystrophy trial, Reuters reported. The move erased about CHF24 billion in market value.
EQUITY | Sep 08, 2026, 05:06 PM UTC
H
Novartis share falls after Phase III HARBOR del-desiran setback
Novartis AG (NVS) shares fell 12.40% premarket after the company said del-desiran failed its Phase III HARBOR study in myotonic dystrophy type 1, with no statistically significant improvement over placebo on hand opening
EQUITY | Sep 08, 2026, 01:16 PM UTC
H
Novartis slips after pelacarsen Phase 3 setback
Novartis traded at $159.99 after pelacarsen flopped in a pivotal Phase 3 cardiovascular trial. Reuters estimated about CHF4.9 billion evaporated from market value as Zurich-listed shares fell 1.9%.
EQUITY | Sep 07, 2026, 05:56 PM UTC
H
Brent tops $97 as German politics, yields pressure European stocks
European stocks ended near flat while Brent climbed above $97, German Bund yields rose and Germany’s AfD won a major state-level vote, deepening political uncertainty.
RATES | Sep 07, 2026, 04:46 PM UTC
H
Novartis jumps ~6% after remibrutinib clears two Phase 3 MS trials
Novartis (NVS) surged about 6% to $161.10 after remibrutinib cleared two Phase 3 trials in multiple sclerosis. The oral drug delivered fewer relapses and brain lesions versus teriflunomide, without raising liver-safety c
EQUITY | Sep 01, 2026, 05:26 PM UTC
M
UK Approves Novartis' Remibrutinib For Adults
Novartis' Remibrutinib approved in UK
EQUITY | Aug 06, 2026, 02:56 PM UTC
L
NVS Novartis receives health Canada approval for Rhapsido® (Remibrutinib tablets) oral treatment for adults with CSU
NVS Novartis receives health Canada approval for Rhapsido® (Remibrutinib tablets) oral treatment for adults with CSU
EQUITY | Jul 27, 2026, 07:21 PM UTC
L
$NVS said it is seeking a preliminary U.S. court injunction to immediately block obesity and Diabetes drug advertisements by LLY
$NVS said it is seeking a preliminary U.S. court injunction to immediately block obesity and Diabetes drug advertisements by LLY
EQUITY | Jul 24, 2026, 10:13 AM UTC
H
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled. IMPORTED GENERIC DRUGS: U.S.
GEOPOLITICS | Jul 22, 2026, 02:08 PM UTC
H
Watch possibly MRK JNJ LLY PFE SNY AZN GSK NVS BMY RHHB after Trump post last night on generic drugs, and 100% tariff brought into US
Watch possibly MRK JNJ LLY PFE SNY AZN GSK NVS BMY RHHB after Trump post last night on generic drugs, and 100% tariff brought into US
GEOPOLITICS | Jul 22, 2026, 10:50 AM UTC
H
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
U.S. President Donald...
GEOPOLITICS | Jul 21, 2026, 11:03 PM UTC
H
Novartis Q2 2026 Earnings Call Transcript
Novartis (NYSE: NVS ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcrip
EARNINGS | Jul 21, 2026, 01:45 PM UTC
H
Morning Movers: Equifax sinks following second quarter earnings
Stock futures are pointing higher as investors attempt to build on Monday's rebound, with technology shares leading premarket gains ahead of a stretch of earnings from some of the market's largest companies. The focus th
RATES | Jul 21, 2026, 01:03 PM UTC
H
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Novartis AG (NYSE: NVS ) reported better-than-expected second-quarter earnings on Tuesday as strong demand for its priority medicines offset the impact of generic competition, while the Swiss drugmaker reaffirmed its ful
EARNINGS | Jul 21, 2026, 12:21 PM UTC
L
NVS said it was suing rival LLY in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss Medicine
NVS said it was suing rival LLY in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss Medicines outperform Novo's drugs.
EQUITY | Jul 21, 2026, 11:38 AM UTC
L
NVS Novartis CEO - we've had an increase in deal-making in China, primarily to license innovations that are developed there to enable them t
NVS Novartis CEO - we've had an increase in deal-making in China, primarily to license innovations that are developed there to enable them to be launched globally - On licensing drugs being developed in China, notes will
RATES | Jul 21, 2026, 11:04 AM UTC
L
NVS Novartis CEO - "no change of plans for me"
NVS Novartis CEO - "no change of plans for me"
EQUITY | Jul 21, 2026, 10:59 AM UTC
H
NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs. EST $14.042B, Q2 core EPS $2.41 vs. EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income
NVS Novartis RESULTS: Q2, Q2 net sales $14.408B vs. EST $14.042B, Q2 core EPS $2.41 vs. EST $2.13, Q2 Net Income $3.257B, Q2 core Net Income $4.578B, Q2 core Operating Income $5.940B, Q2 EPS $1.71, Novartis Earnings Note
RATES | Jul 21, 2026, 10:18 AM UTC
H
Novartis reaffirms FY26 guidance
Net sales expected to...
EARNINGS | Jul 21, 2026, 09:52 AM UTC
L
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year
Reports Q2 net sales...
EARNINGS | Jul 21, 2026, 09:51 AM UTC
L
Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments
Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments
MNA | Jul 06, 2026, 02:15 PM UTC
L
Sector Update: Healthcare Stocks Mixed Premarket Monday
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:18 PM UTC
L
Sector Update: Healthcare
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.4%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:00 PM UTC
H
Update: US Equity Futures Rise Pre-Bell as Chip Stocks Rally, OPEC+ Plans Further Oil Output Boost
() -- (Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.) US equity futures were mostly higher pre-bell Monday as chip stocks rose after losing momentum in the
RATES | Jul 06, 2026, 12:52 PM UTC
L
Reported Earlier: Novartis Receives European Commission Approval For Itvisma To Treat Children With 5q Spinal Muscular Atrophy
Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA)
EQUITY | Jul 02, 2026, 01:49 PM UTC
H
NVS Partners Antares
Novartis partners with Antares Therapeutics to discover, develop, and commercialize small molecule therapies for undruggable oncology targets
EQUITY | Jun 24, 2026, 12:47 PM UTC
H
EU Eases Deportation Rules
The European Parliament has approved a major migration overhaul to simplify deportation procedures and respect fundamental rights and international law.
GEOPOLITICS | Jun 23, 2026, 07:29 PM UTC